BACKGROUND: Recent reports suggest that maternal immunization against low-frequency, platelet (PLT)-specific glycoprotein (GP) polymorphisms is a more common cause of neonatal alloimmune thrombocytopenia (NATP) than previously thought. STUDY DESIGN AND METHODS: Serologic and molecular studies were performed on PLTs and DNA from three families in which an infant was born with apparent NATP not attributable to maternal immunization against known PLT-specific alloantigens. RESULTS: Antibodies reactive only with paternal PLTs were identified in each mother. In Cases 2 (Kno) and 3 (Nos), but not Case 1 (Sta), antibody recognized paternal GPIIb/IIIa in solid-phase assays. Unique mutations encoding amino acid substitutions in GPIIb (Case 2) or GPIIIa (Cases 1 and 3) were identified in paternal DNA and in DNA from two of the affected infants. Antibody from all three cases recognized recombinant GPIIIa (Case 1 [Sta] and Case 3 [Nos]) and GPIIb (Case 2, Kno) mutated to contain the polymorphisms identified in the respective fathers. None of 100 unselected normal subjects possessed the paternal mutations. Enzyme-linked immunosorbent assay and flow cytometric studies suggested that failure of maternal serum from Case 1 (Sta) to react with paternal GPIIIa in solid-phase assays resulted from use of a monoclonal antibody AP2, for antigen immobilization that competed with the maternal antibody for binding to the Sta epitope. CONCLUSION: NATP in the three cases was caused by maternal immunization against previously unreported, low-frequency GP polymorphisms. Maternal immunization against low-frequency PLT-specific alloantigens should be considered in cases of apparent NATP not resolved by conventional serologic and molecular testing.
BACKGROUND: Recent reports suggest that maternal immunization against low-frequency, platelet (PLT)-specific glycoprotein (GP) polymorphisms is a more common cause of neonatal alloimmune thrombocytopenia (NATP) than previously thought. STUDY DESIGN AND METHODS: Serologic and molecular studies were performed on PLTs and DNA from three families in which an infant was born with apparent NATP not attributable to maternal immunization against known PLT-specific alloantigens. RESULTS: Antibodies reactive only with paternal PLTs were identified in each mother. In Cases 2 (Kno) and 3 (Nos), but not Case 1 (Sta), antibody recognized paternal GPIIb/IIIa in solid-phase assays. Unique mutations encoding amino acid substitutions in GPIIb (Case 2) or GPIIIa (Cases 1 and 3) were identified in paternal DNA and in DNA from two of the affected infants. Antibody from all three cases recognized recombinant GPIIIa (Case 1 [Sta] and Case 3 [Nos]) and GPIIb (Case 2, Kno) mutated to contain the polymorphisms identified in the respective fathers. None of 100 unselected normal subjects possessed the paternal mutations. Enzyme-linked immunosorbent assay and flow cytometric studies suggested that failure of maternal serum from Case 1 (Sta) to react with paternal GPIIIa in solid-phase assays resulted from use of a monoclonal antibody AP2, for antigen immobilization that competed with the maternal antibody for binding to the Sta epitope. CONCLUSION: NATP in the three cases was caused by maternal immunization against previously unreported, low-frequency GP polymorphisms. Maternal immunization against low-frequency PLT-specific alloantigens should be considered in cases of apparent NATP not resolved by conventional serologic and molecular testing.
Authors: P Metcalfe; N A Watkins; W H Ouwehand; C Kaplan; P Newman; R Kekomaki; M De Haas; R Aster; Y Shibata; J Smith; V Kiefel; S Santoso Journal: Vox Sang Date: 2003-10 Impact factor: 2.144
Authors: Andre C Schuh; Nick A Watkins; Quang Nguyen; Nicholas J Harmer; Martin Lin; Joseph Y A Prosper; Kate Campbell; D Robert Sutherland; Paul Metcalfe; Wendy Horsfall; Willem H Ouwehand Journal: Blood Date: 2002-03-01 Impact factor: 22.113
Authors: Julie A Peterson; Shannon M Pechauer; Maria L Gitter; Adam Kanack; Brian R Curtis; Jeff Reese; Vasudeva M Kamath; Janice G McFarland; Richard H Aster Journal: Transfusion Date: 2011-11-09 Impact factor: 3.157
Authors: Mary Beth Callan; Petra Werner; Nicola J Mason; Geralyn M Meny; Michael G Raducha; Paula S Henthorn Journal: Comp Med Date: 2013-08 Impact factor: 0.982
Authors: Julie A Peterson; Maria Gitter; Daniel W Bougie; Shannon Pechauer; Kathleen A Hopp; Brad Pietz; Aniko Szabo; Brian R Curtis; Janice McFarland; Richard H Aster Journal: Transfusion Date: 2013-10-16 Impact factor: 3.157
Authors: Ulrich J Sachs; Tamam Bakchoul; Olga Eva; Astrid Giptner; Gregor Bein; Richard H Aster; Maria Gitter; Julie Peterson; Sentot Santoso Journal: Thromb Haemost Date: 2011-11-24 Impact factor: 5.249
Authors: Julie A Peterson; Shannon M Pechauer; Maria L Gitter; Aniko Szabo; Brian R Curtis; Richard H Aster Journal: Transfusion Date: 2012-04 Impact factor: 3.157
Authors: Julie A Peterson; Adam Kanack; Dhirendra Nayak; Daniel W Bougie; Janice G McFarland; Brian R Curtis; Richard H Aster Journal: Transfusion Date: 2012-09-25 Impact factor: 3.157